Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Give written informed consent to participate in the study, after having received all information relating to the design, aims and possible risks resulting therefrom.~* Common symptoms of persistent, daily, mild to moderate dry eye lasting more than three months: OSDI scale between 13-70 and VAS scale between 2 -7.~* Eye tests in both eyes: Corneal fluorescein staining (Oxford scale \> 0), Tear break-up time \< 10 seconds and Schirmer's test with anaesthesia \< 10 mm/5min.~Exclusion criteria:~* Women who are pregnant or breastfeeding or who have a positive urine pregnancy test. Women who do not commit to use a medically acceptable method of contraception from the time of selection and throughout the study.~* Any current, relevant disease, including respiratory disease, cardiovascular disease, endocrine disease, neurological disease, haematological disease, kidney disease, oncological disease, liver disease, gastrointestinal dysfunction, hypertension or active acute infectious processes.~* Previous chronic or recurrent processes which, according to the investigator, could affect the development of the study.~* Concomitant use of other medications with analgesic activity by any route of administration at the time of entry into the study.~* Change in any concomitant eye and/or systemic medication of the patient one month before the study and during the study.~* Changes in the pre-established administration schedule of artificial tears during the 15 days before the study and during the 10 days of the study.~* Initiation of treatment with cyclosporine or changes in the dosage or administration schedule of cyclosporine within the 6 months before inclusion in the study.~* History of hypersensitivity to drugs.~* Use of contact lenses during the treatment and previous 15 days.~* History of drug abuse or drug or alcohol dependence.~* Laboratory abnormalities which, in the investigator's opinion, are clinically significant.~* Previous refractive surgery.~* Having participated in another clinical trial within the 2 months prior to inclusion.~* Another eye disease that is significant in the investigator's opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYL1001 eye drops dose C (Type: EXPERIMENTAL): SYL1001 eye drops dose C administration via the ophthalmic route
- SYL1001 eye drops dose D (Type: EXPERIMENTAL): SYL1001 eye drops dose D administration via the ophthalmic route
- Placebo (Type: PLACEBO_COMPARATOR): Placebo eye drops administration via the ophthalmic route

Based on this trial design, predict the completion outcome and termination type (if applicable).